Biocon

Biocon Limited
TypePublic
BSE: 532523
NSE: BIOCON
ISININE376G01013
Industry
Founded1978 (1978)
FounderKiran Mazumdar-Shaw
Headquarters,
India
Key people
  • Kiran Mazumdar-Shaw (executive chairperson)
  • Shreehas P Tambe (CEO & Managing Director, Biocon Limited)
Products
  • Biologics
  • Small molecules
  • Branded formulations
  • Research services
RevenueIncrease ₹16,470 crore (US$1.7 billion) (2025)
Increase ₹4,374 crore (US$450 million) (2025)
Decrease ₹1,013 crore (US$110 million) (2025)
Total assetsIncrease ₹58,797 crore (US$6.1 billion) (2025)
Total equityIncrease ₹27,712 crore (US$2.9 billion) (2025)
Number of employees
16,545 (March 2023)
Subsidiaries
  • Biocon Biologics
  • Syngene International
Websitewww.biocon.com
Footnotes
Financials as of 31 March 2025.

Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb (Itolizumab) and KRABEVA (Bevacizumab).

Syngene International Limited (Syngene) is a publicly listed subsidiary of Biocon, operating in the contract research and development organization.